JP2022533418A5 - - Google Patents
Info
- Publication number
- JP2022533418A5 JP2022533418A5 JP2021569109A JP2021569109A JP2022533418A5 JP 2022533418 A5 JP2022533418 A5 JP 2022533418A5 JP 2021569109 A JP2021569109 A JP 2021569109A JP 2021569109 A JP2021569109 A JP 2021569109A JP 2022533418 A5 JP2022533418 A5 JP 2022533418A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- nos
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852039P | 2019-05-23 | 2019-05-23 | |
| US62/852,039 | 2019-05-23 | ||
| PCT/US2020/034281 WO2020237173A1 (en) | 2019-05-23 | 2020-05-22 | Anti-ror1/anti-cd3 bispecific binding molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533418A JP2022533418A (ja) | 2022-07-22 |
| JP2022533418A5 true JP2022533418A5 (enExample) | 2023-05-24 |
| JP7611171B2 JP7611171B2 (ja) | 2025-01-09 |
Family
ID=71078637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569109A Active JP7611171B2 (ja) | 2019-05-23 | 2020-05-22 | 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220227866A1 (enExample) |
| EP (1) | EP3972999A1 (enExample) |
| JP (1) | JP7611171B2 (enExample) |
| KR (1) | KR20220012313A (enExample) |
| CN (1) | CN113874399B (enExample) |
| AU (1) | AU2020277489A1 (enExample) |
| BR (1) | BR112021023026A2 (enExample) |
| CA (1) | CA3139111A1 (enExample) |
| MX (1) | MX2021014193A (enExample) |
| TW (1) | TWI899079B (enExample) |
| WO (1) | WO2020237173A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023504620A (ja) * | 2019-12-06 | 2023-02-06 | オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物 |
| KR20220139916A (ko) * | 2020-02-07 | 2022-10-17 | 벨로스바이오 인코포레이티드 | 항-ror1 항체 및 조성물 |
| US20240392003A1 (en) * | 2021-02-02 | 2024-11-28 | Numab Therapeutics AG | Multispecific antibodies having specificity for ror1 and cd3 |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| US12545716B2 (en) | 2021-07-19 | 2026-02-10 | Immunome, Inc. | Immunoconjugates and methods |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2023000791A1 (en) * | 2021-07-23 | 2023-01-26 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against ror1 and uses thereof |
| KR20240082402A (ko) * | 2021-10-07 | 2024-06-10 | 내셔날 리서치 카운실 오브 캐나다 | 항-cd3 단일클론 항체 및 치료용 작제물 |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3803790B2 (ja) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| CA2881966C (en) * | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| CA2899577C (en) | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| WO2015063339A1 (en) * | 2013-11-04 | 2015-05-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| KR102638104B1 (ko) * | 2014-07-25 | 2024-02-20 | 메모리얼 슬로안 케터링 캔서 센터 | 이특이적 her2 및 cd3 결합 분자 |
| CA2963692A1 (en) * | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3091032A1 (en) * | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
| EP3405492B1 (en) * | 2016-01-21 | 2020-10-21 | Novartis AG | Multispecific molecules targeting cll-1 |
| JP2019506158A (ja) * | 2016-01-22 | 2019-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｒｏｒ１抗体、ｒｏｒ１×ｃｄ３二重特異性抗体、及びそれらの使用法 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| EP3574018A4 (en) * | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE |
| CA3067829A1 (en) * | 2017-06-23 | 2018-12-27 | VelosBio Inc. | Ror1 antibody immunoconjugates |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| KR20220139916A (ko) * | 2020-02-07 | 2022-10-17 | 벨로스바이오 인코포레이티드 | 항-ror1 항체 및 조성물 |
-
2020
- 2020-05-22 EP EP20732061.5A patent/EP3972999A1/en active Pending
- 2020-05-22 US US17/613,251 patent/US20220227866A1/en active Pending
- 2020-05-22 CN CN202080038180.6A patent/CN113874399B/zh active Active
- 2020-05-22 TW TW109117258A patent/TWI899079B/zh active
- 2020-05-22 MX MX2021014193A patent/MX2021014193A/es unknown
- 2020-05-22 WO PCT/US2020/034281 patent/WO2020237173A1/en not_active Ceased
- 2020-05-22 JP JP2021569109A patent/JP7611171B2/ja active Active
- 2020-05-22 KR KR1020217041982A patent/KR20220012313A/ko not_active Withdrawn
- 2020-05-22 BR BR112021023026A patent/BR112021023026A2/pt unknown
- 2020-05-22 AU AU2020277489A patent/AU2020277489A1/en active Pending
- 2020-05-22 CA CA3139111A patent/CA3139111A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| CN109071666B (zh) | 人脊髓灰质炎病毒受体(pvr)特异性抗体 | |
| US20190144540A1 (en) | Antibodies specific to delta 1 chain of t cell receptor | |
| JP2022526764A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| WO2019214624A1 (en) | Fully human antibodies against ox40, method for preparing same, and use thereof | |
| ME02377B (me) | Anti-igf antitijela | |
| JP7692422B2 (ja) | 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用 | |
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2023518153A5 (enExample) | ||
| CN112625128B (zh) | 抗ngf抗体及其抗原结合片段、其制备方法和应用 | |
| JP2022532991A5 (enExample) | ||
| CN115210261A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| JP2025513721A5 (enExample) | ||
| JP2022550327A (ja) | 新規の抗ｐｄ－ｌ１抗体 | |
| WO2021057930A1 (en) | A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2025513593A5 (enExample) | ||
| JP2021516670A (ja) | 抗ｔｒａｉｌｒ２抗体−毒素−複合体およびその抗腫瘍治療における薬物用途 | |
| WO2021169986A1 (en) | A bifunctional fusion protein and uses thereof | |
| JP7196311B2 (ja) | 抗ｔｉｍ－３抗体とその利用 | |
| EP4196500A2 (en) | Cancer treatment methods using anti-cd73 antibodies | |
| CN107106676A (zh) | 用于治疗肉瘤的组合物和方法 | |
| RU2021137832A (ru) | Анти-ror1/анти-cd3 биспецифические связывающие молекулы | |
| CN118047867B (zh) | 一种抗bcma的纳米抗体、抗体及其应用 |